Pfizer Persists: Big Opportunities And Challenges In Vaccines
Executive Summary
The big pharma has two vaccines that have progressed to late-stage development, one for Clostridium difficile infection and the other for Staph aureus. Both represent big commercial opportunities, but bringing a new vaccine to market is a slow process.
You may also be interested in...
Pfizer Holds Out Hope For C. Diff Vaccine Despite Clinical, Commercial Failures
Pfizer’s Clostridioides difficile vaccine candidate missed a Phase III primary endpoint but the company may seek a path forward based on secondary endpoints even after past failures in the field.
More Vaccine Disappointment For Sanofi As First C Diff Toxoid Vaccine Fails
A second dose of bad news for Sanofi's vaccines unit sees its C. difficile vaccine dropped after a Phase III study was deemed unlikely to succeed.
Pfizer Staph Vaccine Trial May Support Claim For Some, But Not All, Orthopedic Surgeries
US FDA advisory committee members say if SA4Ag is efficacious in ongoing trial of spinal surgery patients, efficacy data could support a broader claim encompassing limited number of other orthopedic procedures with similar pathophysiology and infection risk, such as hip and knee replacement surgeries.